Long-term study of navenibart for hereditary angioedema
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests navenibart over a longer period to see if it continues to prevent swelling attacks in people with hereditary angioedema. It is for people who were already in a previous navenibart study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier STAR-0215-301 study and either completed it or left it after getting two doses and two months of follow-up.
- You cannot have taken part in any other research drug study in the past 30 days.
- You cannot have used ACE inhibitors or estrogen-containing medications (like birth control or hormone therapy) in the 30 days before screening.
- You must not have a known allergy to any ingredient in navenibart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study looks at how well a drug called garadacimab works and how safe it is for people with hereditary angioedema (HAE), a condition that causes sudden swelling. It tests the drug in people who are starting it for the first time as part of their regular care.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.